Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvage surgery plus Nimotuzumab and Camrelizumab for locally recurrent nasopharyngeal carcinoma
ChiCTR2100047135Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nimotuzumab and camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: 2-year overall survival rate. Started Jun 2021; status: recruiting.
02
Drugs
nimotuzumabcamrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100047135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047135.